Combination of PD-991 and letrozole improves survival in patients with HER2- breast c

[News]

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

More... (http://www.news-medical.net/news/20121206/Combination-of-PD-991-and-letrozole-improves-survival-in-patients-with-HER2-breast-cancer.aspx)